2021 IUBMB January News

2021 IUBMB January News

2021 JANUARY NEWS
CONGRATULATIONS
IUBMB Wood-Whelan Fellows

Maria Azparren

Keila Belhart

Sabrina Vallone

Constanza Ballesteros Martinez

Maria Andrea Camiletti

Paula Vincino

Oswald Djihinto

IUBMB Mid-Career Fellows

Mirza Saqib Baig

Laura Ruth Delgui

Afolabi-Balogun Nusrah Bolatito

Uzma Saquib

ALL FELLOWSHIPS DEADLINE:
*APRIL 1st, 2021*

Supports up to 2 months in a lab and up to a maximum of US $5,000 for travel expenses

Read more on Wood-Whelan Fellowships


Supports up to 4 months in a lab and up to a maximum of US $4,000 for travel expenses

Read more on Mid-Career Fellowships


Supports educators visiting another institution to either advise/teach or learn

Read more on Tang Education Fellowships

NEW Fellowships

IUBMB Travel Fellowships are designated to support biochemistry and molecular biology trainees such as graduate students and postdoctoral fellowsGo to:
https://iubmb.org/activities/fellowship-programs/iubmb-travel-fellowships/


IUBMB MilliporeSigma Virtual Meeting Fellowships are designated to support biochemistry and molecular biology trainees such as graduate students and postdoctoral fellowsGo to:
https://iubmb.org/activities/fellowship-programs/iubmb-milliporesigma-virtual-meeting-fellowships/

IUBMB JOURNALS

  • Toll‐like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonistsThe ability of Toll‐like receptors (TLRs) in distinguishing “self” and “non‐self” antigens is a cornerstone in the innate immunity system; however, their misregulation links inflammatory responses to the development of a wide range of human cancers. Generally, while chronic low‐grade TLR activation favors a tumor‐promoting state, high‐dose TLR activation induces antitumor responses. This issue sheds light on the controversial role of these receptors in human cancers as double‐edged swords, and further highlights the therapeutic efficacy of both TLR agonists and antagonists in cancer treatment strategies.


  • Effects of different autophagy inhibitors on sensitizing KG‐1 and HL‐60 leukemia cells to chemotherapyAutophagy, a highly‐conserved catabolic process that is responsible for maintaining cell survival and homeostasis under different stressful conditions, is critically involved during chemotherapy with anti‐leukemic drugs, including arsenic trioxide (ATO) and/or all‐trans retinoic acid (ATRA). The blockade of autophagy flux at the late stages, especially with the lysosome inhibitor of hydroxyquinoline, rather than its total blockade using the early upstream inhibitor of 3‐Methyladenine, markedly potentiates anti‐leukemic and apoptotic effects of ATO/ATRA in KG1 leukemic stem‐like cells but not HL‐60 cells. The autophagy manipulation may enhance the effectiveness of chemotherapy in leukemia cells in a cell‐ and context‐dependent manner.


Introducing IUBMB Life’s new Editor-in-Chief: Efstathios S. Gonos

Efstathios S. Gonos began his new role as Editor-in-Chief of IUBMB Life
on January 1st, 2021.

Click here for more information

We would also like to welcome the new Associate Editors and Assistant Editor to IUBMB Life

ASSOCIATE EDITORS
Jianping Ding| Chinese Academy of Sciences, Shanghai Institute of Biochemistry and Cell Biology, Shanghai, China
Jeanette Erdmann| University of Lübeck, Institute for Cardiogenetics, Lubeck, Germany
Toni Gabaldón| Institute for Research in Biomedicine & Barcelona Supercomputing Centre, Barcelona, SpainDominic Ng| University of Queensland, Faculty of Medicine, Brisbane, Australia
Mary Reyland| University of Colorado, Department of Craniofacial Biology, Aurora, USA
Yi-Ching Wang| National Cheng Kung University, College of Medicine, Tainan, Taiwan
ASSISTANT EDITOR
Sophia Athanasopoulou| National Hellenic Research Foundation, Institute of Chemical Biology, Athens, Greece

Click here to see the Editorial Board





UPCOMING MEETING

LS2 online flyer

General registration deadline until29 January 2021|https://annual-meeting.ls2.ch/registration